PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ritlecitinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

27 hits

Bibliografisk träff 2024-09-01

Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.

Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE.

J Crohns Colitis · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1093/ecco-jcc/jjad213

Bibliografisk träff 2023-12-05

LITFULO<sup>TM</sup> (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata.

Gupta AK, Ravi SP, Vincent K, Abramovits W.

Skinmed · journal article

Bibliografisk träff 2023-11-15

Ritlecitinib

Författaruppgift saknas

Journal missing · review

Bibliografisk träff 2023-11-02

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development.

Wojciechowski J, S Purohit V, Huh Y, Banfield C, Nicholas T.

Clin Pharmacokinet · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s40262-023-01318-3

Bibliografisk träff 2023-09-29

Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.

Martin DA, Telliez JB, Pleasic-Williams S, Zhang Y, Tierney B, Blatnik M, Gale JD, Banfield C, Zhou Y, Lejeune A, Zwillich SH, Stevens E, Tiwari N, Kieras E, Karanam A.

J Clin Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1002/jcph.2347

Bibliografisk träff 2023-09-28

Improvements in immune/melanocyte biomarkers with JAK3/TEC family kinase inhibitor ritlecitinib in vitiligo.

Guttman-Yassky E, Del Duca E, Da Rosa JC, Bar J, Ezzedine K, Ye Z, He W, Hyde C, Hassan-Zahraee M, Yamaguchi Y, Peeva E.

J Allergy Clin Immunol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.jaci.2023.09.021

Bibliografisk träff 2023-09-21

JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis.

Lo Pizzo M, La Barbera L, Rizzo C, Mohammadnezhad L, Camarda F, Ciccia F, Guggino G.

Clin Exp Rheumatol · journal article · DOI 10.55563/clinexprheumatol/hhcnmt

Bibliografisk träff 2023-09-14

Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.

Thaçi D, Tziotzios C, Ito T, Ko J, Karadağ AS, Fang H, Edwards RA, Bonfanti G, Wolk R, Tran H, Law E.

Dermatol Ther (Heidelb) · research-article; journal article · DOI 10.1007/s13555-023-00997-x

Bibliografisk träff 2023-09-01

Ritlecitinib: First Approval.

Blair HA.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-023-01928-y

Bibliografisk träff 2023-08-10

Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.

Huh Y, Plotka A, Wei H, Kaplan J, Raha N, Towner J, Purohit VS, Dowty ME, Wolk R, Vourvahis M, King-Ahmad A, Mathialagan S, West MA, Lazzaro S, Ryu S, Rodrigues AD.

Pharm Res · research-article; journal article · DOI 10.1007/s11095-023-03564-3

Bibliografisk träff 2023-08-01

Effect of Janus Kinase 3 Inhibitor on Sebaceous Gland Regeneration during Skin Wound Healing.

Jo WT, Kim AY, Woo HG, Song HJ, Baik EJ.

Ann Dermatol · research-article; journal article · DOI 10.5021/ad.22.204

Bibliografisk träff 2023-07-17

Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.

Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H.

Pediatr Dermatol · clinical trial, phase iii; clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1111/pde.15378

Bibliografisk träff 2023-07-05

A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areata.

King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R.

Immunotherapy · patient education handout · DOI 10.2217/imt-2023-0069

Bibliografisk träff 2023-06-28

Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.

Sardana K, Bathula S, Khurana A.

Indian Dermatol Online J · review-article; review; journal article · DOI 10.4103/idoj.idoj_452_22

Bibliografisk träff 2023-04-14

Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.

King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R.

Lancet · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)00222-2

Bibliografisk träff 2023-04-05

Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.

Wang X, Purohit V, Dowty ME, Rodrigues D, Luo L, Mathialagan S, Carey W, Plotka A, Kalluru H, Melissa O, Kaplan J, Huh Y, Vourvahis M, Wolk RM.

J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1002/jcph.2215

Bibliografisk träff 2023-03-28

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics.

Purohit V, Huh Y, Wojciechowski J, Plotka A, Salts S, Antinew J, Dimitrova A, Nicholas T.

AAPS J · research support, non-u.s. gov't; research-article; journal article · DOI 10.1208/s12248-023-00792-8

Bibliografisk träff 2023-03-05

Efficacy of PF-06651600 in alleviating the pro-inflammatory capacity of CD4<sup>+</sup> T cells in rheumatoid arthritis patients.

Mohammad TAM.

Int J Rheum Dis · journal article · DOI 10.1111/1756-185x.14643

Bibliografisk träff 2023-03-02

Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants.

Liu J, Solan R, Wolk R, Plotka A, O'Gorman MT, Winton JA, Kaplan J, Purohit VS.

Br J Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1111/bcp.15695

Bibliografisk träff 2023-01-06

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.

Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE.

Clin Gastroenterol Hepatol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.cgh.2022.12.029

Bibliografisk träff 2022-09-01

Low-Dose JAK3 Inhibition Improves Antitumor T-Cell Immunity and Immunotherapy Efficacy.

Dammeijer F, van Gulijk M, Klaase L, van Nimwegen M, Bouzid R, Hoogenboom R, Joosse ME, Hendriks RW, van Hall T, Aerts JG.

Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-21-0943

Bibliografisk träff 2022-02-17

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

Ramírez-Marín HA, Tosti A.

Drug Des Devel Ther · review-article; review; journal article · DOI 10.2147/dddt.s334727

Bibliografisk träff 2022-01-25

Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

Winnette R, Banerjee A, Sikirica V, Peeva E, Wyrwich K.

J Eur Acad Dermatol Venereol · clinical trial, phase ii; research-article; randomized controlled trial; journal article · DOI 10.1111/jdv.17909

Bibliografisk träff 2021-12-20

Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.

Eisman S, Sinclair R.

Expert Opin Investig Drugs · clinical trial, phase ii; randomized controlled trial; journal article · DOI 10.1080/13543784.2021.2012149

Bibliografisk träff 2021-03-20

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.

King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L, Banfield C, Page K, Zhang W, Vincent MS.

J Am Acad Dermatol · clinical trial, phase ii; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.jaad.2021.03.050

Bibliografisk träff 2020-09-07

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banfield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS.

Arthritis Rheumatol · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1002/art.41316

Bibliografisk träff 2019-05-22

PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.

Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, Nguyen C, Everley RA, Trujillo JI, Johnson DS, Point GR, Thorarensen A, Kilty I, Telliez JB.

ACS Chem Biol · journal article · DOI 10.1021/acschembio.9b00188